Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study

• DOI: 10.1136/rmdopen-2022-002534
• Publication Date: 2023-03-31T14:12:48Z
• Authors: Charlotte Laurent; Laure Ricard; Yann Nguyen; Jean Jacques Boffa; Eric Rondeau; Grigorios Gerotzi...; Ismail Elalamy; Sophie Deriaz; Claire De Moreuil; Virginie Planche; Cathererine Johanet; Francois Millot; Olivier Fain; Arsène Mekinian
• Keywords: Pregnancy; Placenta; R; Antibodies, Antiphospholipid; Medicine; Humans; Autoimmunity; Female; Thrombosis; Antiphospholipid Syndrome; Prognosis; 3. Good health; Retrospective Studies

Objective Antiphospholipid syndrome (APS) is defined by the association of thromboembolic and/or obstetrical clinical manifestations and presence antiphospholipid antibodies. The objective our study was to evaluate impact triple-positive profile in a cohort 204 APS patients. Methods We conducted retrospective study, including patients with primary or secondary APS, meeting Sydney criteria at least one thrombotic complication. Clinical characteristics risk relapse (defined occurrence new event adverse event) between non-triple-positive were compared. Results included 68 136 single double positive. 122 (59.8%) had APS. 67 (32.8%) higher rate among (45.6% vs 26.5%, p=0.010), 170 (83.3%) without difference others. Thrombotic events more often venous (56.4%) than arterial (37.7%). Triple-positive placental complications others (17.6% 2.9%, p=0.001) non-criteria (48.5% 25.7%, p=0.002). Among events, there frequency Sneddon (7.4% 0.7%, p=0.028). (63.2% 39,7%, p=0002). In multivariate analysis, associated (HR 1.63; 95% CI 1.04 2.55; p=0.031). Conclusion triple-positivity complications.